GlassScriptPhysician profile
Eugenie Du
NPI 1700178241
$444.38
in general payments reported to CMS, 2019-2025
10 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Sleep Medicine (Otolaryngology) provider received nationally (typical 2025 total: $509).
See the full distribution for Sleep Medicine (Otolaryngology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.22 · 2022: $79.92 · 2023: $52.72 · 2024: $94.96 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $119.94 | 2022-2024 | Imfinzi, Enhertu, Lynparza |
| Inspire Medical Systems, INC. | $104.58 | 2025 | Inspire |
| Sobi, INC | $32.96 | 2025 | |
| Seagen INC. | $29.96 | 2022 | |
| Karyopharm Therapeutics INC. | $28.57 | 2025 | Xpovio |
| Medtronic, INC. | $28.45 | 2025 | Propel |
| Gilead Sciences, INC. | $27.74 | 2023 | |
| Eisai INC. | $24.98 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.98 | 2022 | |
| Davol INC. | $22.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenie Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.